The evolution of and evidence for opportunistic salpingectomy

Obstetrics and Gynecology

Volumn 130, Issue 4, 2017, Pages 814-824

  Dilley, Sarah E ^a   Straughn, J Michael ^a   Leath, Charles A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CLINICAL OUTCOME; FEMALE; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; OVARY CANCER; OVARY FUNCTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; REVIEW; RISK REDUCTION; SALPINGECTOMY; SURGICAL RISK; UNITED STATES; UTERINE TUBE LIGATION; VAGINAL HYSTERECTOMY; CLINICAL PRACTICE; HEALTH SERVICE; HYSTERECTOMY; MORTALITY; OVARIAN NEOPLASMS; PROPHYLACTIC SURGICAL PROCEDURE; UTILIZATION;

FEMALE; HUMANS; HYSTERECTOMY; OVARIAN NEOPLASMS; PRACTICE PATTERNS, PHYSICIANS'; PROPHYLACTIC SURGICAL PROCEDURES; SALPINGECTOMY; UNITED STATES; WOMEN'S HEALTH SERVICES;

EID: 85030611380     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000002243     Document Type: Review

References (68)

1. American Cancer Society. Ovarian cancer. Available at: http://www.cancer.org/cancer/ovariancancer/detailedguide/ovariancancer-key-statistics. Retrieved January 13, 2017.
2. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER cancer statistics review, 1975-2013. 2016: based on November 2015 SEER data submission, posted to the SEER website; 2016. Available at: https://seer.cancer. gov/archive/csr/1975-2013/. Retrieved February 1, 2017.
3. Lowe KA, Chia VM, Taylor A, O?Malley C, Kelsh M, Mohamed M, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013; 130: 107-14.
4. Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Cancer 2016; 143: 270-5.
5. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016; 387: 945-56.
6. Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 2015; 121: 2108-20.
7. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol 2015; 213: 262-7.
8. Fathalla MF. Incessant ovulation-A factor in ovarian neoplasia? Lancet 1971; 2: 163.
9. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-6.
10. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-90.
11. Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? [Published erratum appears in Am J Surg Pathol 2010; 34: 1891]. Am J Surg Pathol 2010; 34: 1407-16.
12. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-9.
13. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-6.
14. Sherman-Baust CA, Kuhn E, Valle BL, Shih IeM, Kurman RJ, Wang TL, et al A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol 2014; 233: 228-37.
15. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-43.
16. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-31.
17. Dietl J. Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Arch Gynecol Obstet 2014; 289: 241-6.
18. Wright JD, Herzog TJ, Tsui J, Ananth CV, Lewin SN, Lu YS, et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol 2013; 122: 233-41.
19. Doll KM, Dusetzina SB, Robinson W. Trends in inpatient and outpatient hysterectomy and oophorectomy rates among commercially insured women in the United States, 2000-2014. JAMA Surg 2016; 151: 876-7.
20. Cohen SL, Ajao MO, Clark NV, Vitonis AF, Einarsson JI. Outpatient hysterectomy volume in the United States. Obstet Gynecol 2017; 130: 130-137.
21. Mikhail E, Salemi JL, Mogos MF, Hart S, Salihu HM, Imudia AN. National trends of adnexal surgeries at the time of hysterectomy for benign indication, United States, 1998-2011. Am J Obstet Gynecol 2015; 213: 713.e1-13.
22. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian Conservation at the time of hysterectomy and long-Term health outcomes in the nurses? health study. Obstet Gynecol 2009; 113: 1027-37.
23. Chan LM, Westhoff CL. Tubal sterilization trends in the United States. Fertil Steril 2010; 94: 1-6.
24. Bartz D, Greenberg JA. Sterilization in the United States. Rev Obstet Gynecol 2008; 1: 23-32.
25. The Society of Gynecologic Oncology of Canada. GOC statement regarding salpingectomy and ovarian cancer prevention. 2011. Available at: http://g-o-c.org/wp-content/uploads/2015/09/7GOCStmt-2011SepśalpOvCa-EN.pdf. Retrieved February 1, 2017.
26. Society of Gynecologic Oncology. SGO clinical practice statement: salpingectomy for ovarian cancer prevention. Chicago (IL): Society of Gynecologic Oncology; 2013.
27. Salpingectomy for ovarian cancer prevention. Committee Opinion No. 620. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015; 125: 279-81.
28. Creinin MD, Zite N. Female tubal sterilization: the time has come to routinely consider removal. Obstet Gynecol 2014; 124: 596-9.
29. Gilks CB, Miller D. Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: the time has come. Gynecol Oncol 2013; 129: 443-4.
30. McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014; 210: 471.e1-11.
31. Sandoval C, Fung-Kee-Fung M, Gilks B, Murphy KJ, Rahal R, Bryant H. Examining the use of salpingectomy with hysterectomy in Canada. Curr Oncol 2013; 20: 173-5.
32. Hanley GE, McAlpine JN, Pearce CL, Miller D. The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol 2017; 216: 270.e1-9.
33. Garcia C, Martin M, Tucker LY, Lyon L, Armstrong MA, McBride-Allen S, et al. Experience with opportunistic salpingectomy in a large, community-based health system in the United States. Obstet Gynecol 2016; 128: 277-83.
34. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-Analysis. Hum Reprod Update 2010; 17: 55-67.
35. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-Analysis. J Ovarian Res 2012; 5: 13.
36. Merritt MA, De Pari M, Vitonis AF, Titus LJ, Cramer DW, Terry KL. Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod 2013; 28: 1406-17.
37. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 2013; 42: 579-89.
38. Miller DM, McAlpine JN, Gilks CB, Huntsman DG. Opportunistic salpingectomy: the way forward-response to Steven Narod. Curr Oncol 2013; 20: 143-4.
39. Narod SA. Salpingectomy to prevent ovarian cancer: a countercurrents series. Curr Oncol 2013; 20: 145-7.
40. Lessard-Anderson CR, Handlogten KS, Molitor RJ, Dowdy SC, Cliby WA, Weaver AL, et al. Effect of tubal sterilization technique on risk of serous ovarian and primary peritoneal carcinoma. Gynecol Oncol 2014; 135: 423-7.
41. Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand 2015; 94: 86-94.
42. Falconer H, Yin L, Grönberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015; 107: dju410.
43. Yoon SH, Kim SN, Shim SH, Kang SB, Lee SJ. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-Analysis. Eur J Cancer 2016; 55: 38-46.
44. Herzog TJ, Dinkelspiel HE. Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal? Curr Oncol 2013; 20: 148-51.
45. Manchanda R, Menon U. Opportunistic bilateral salpingectomy (OBS) for the prevention of ovarian cancer should be offered in the context of a clinical trial: FOR: there is lack of clarity on a number of key issues. BJOG 2016; 123: 463.
46. Tanner EJ, Long KC, Visvanathan K, Fader AN. Prophylactic salpingectomy in premenopausal women at low risk for ovarian cancer: risk-reducing or risky? Fertil Steril 2013; 100: 1530-1.
47. Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol 2013; 129: 448-51.
48. Vorwergk J, Radosa MP, Nicolaus K, Baus N, Jimenez Cruz J, Rengsberger M, et al. Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol 2014; 140: 859-65.
49. Minig L, Chuang L, Patrono MG, Cárdenas-Rebollo JM, García-Donas J. Surgical outcomes and complications of prophylactic salpingectomy at the time of benign hysterectomy in premenopausal women. J Minim Invasive Gynecol 2015; 22: 653-7.
50. Brummer TH, Jalkanen J, Fraser J, Heikkinen AM, Kauko M, Mäkinen J, et al. FINHYST, a prospective study of 5279 hysterectomies: complications and their risk factors. Hum Reprod 2011; 26: 1741-51.
51. Ye X, Yang YZ, Sun XX A retrospective analysis of the effect of salpingectomy on serum antiMüllerian hormone level and ovarian reserve. Am J Obstet Gynecol 2015; 212: 53.e1-10.
52. Grynnerup AG, Lindhard A, Sørensen S. Anti-Müllerian hormone levels in salpingectomized compared with nonsalpingectomized women with tubal factor infertility and women with unexplained infertility. Acta Obstet Gynecol Scand 2013; 92: 1297-303.
53. Venturella R, Lico D, Borelli M, Imbrogno MG, Cevenini G, Zupi E, et al. 3 to 5 years later: long-Term effects of prophylactic bilateral salpingectomy on ovarian function. J Minim Invasive Gynecol 2017; 24: 145-150.
54. Findley AD, Siedhoff MT, Hobbs KA, Steege JF, Carey ET, McCall CA, et al. Short-Term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril 2013; 100: 1704-8.
55. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100: 630-41.
56. Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, et al. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol 2015; 125: 338-45.
57. Dilley SE, Havrilesky LJ, Bakkum-Gamez J, Cohn D, Michael Straughn J Jr, Caughey AB, et al. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol 2017; 146(2): 373-379.
58. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the U. S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174: 1161-8.
59. Bollapragada SS, Bandyopadhyay S, Serle E, Baird C. Spontaneous pregnancy after bilateral salpingectomy. Fertil Steril 2005; 83: 767-8.
60. Kahyaoglu S, Yeral I, Artar I, Simsek S, Kahyaoglu I, Mollamahmutoglu L, et al. Intra-uterine spontaneous viable twin pregnancy after bilateral salpingectomy. Eur J Obstet Gynecol Reprod Biol 2011; 159: 232-3.
61. Soderstrom RM. Sterilization failures and their causes. Am J Obstet Gynecol1985; 152: 395-403.
62. Danis RB, Della Badia CR, Richard SD. Postpartum permanent sterilization: could bilateral salpingectomy Replace bilateral tubal ligation? J Minim Invasive Gynecol 2016; 23: 928-32.
63. Salpingectomy at cesarean delivery for ovarian cancer reduction (SCORE). Available at: https://clinicaltrials.gov/show/NCT02374827. Retrieved January 12, 2017.
64. Kho RM, Magrina JF. Round ligament technique and use of a vessel-sealing device to facilitate complete salpingectomy at the time of vaginal hysterectomy. J Minim Invasive Gynecol 2015; 22: 1084-7.
65. Robert M, Cenaiko D, Sepandj J, Iwanicki S. Success and complications of salpingectomy at the time of vaginal hysterectomy. J Minim Invasive Gynecol 2015; 22: 864-9.
66. ClinicalTrials.gov. Available at: clinicaltrials.gov. Retrieved March 7, 2017.
67. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol 2014; 133: 283-6.
68. Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013; 121: 14-24.